sellWeak10b5-1 plan
David F Novack sold $1.8M of DVAX
President & COO at DYNAVAX TECHNOLOGIES CORP. 114,000 shares at an average of $15.64, traded Jan 15, 2026, filed Jan 20, 2026.
Warning score
30Value
$1.8M
114,000 shares
Holdings after
63,344
-64% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RolePresident
- +25Trade size$1.8M at market
- +20Share of holdings soldSold 64% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001628280-26-002640, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | MOption exercise Common Stock10b5-1 | +20,000 | $6.81 | $136k | 83,344 | Jan 20, 2026 |
| Jan 15, 2026 | MOption exercise Common Stock10b5-1 | +94,000 | $10.47 | $984k | 177,344 | Jan 20, 2026 |
| Jan 15, 2026 | SOpen-market sale Common Stock10b5-1 | -114,000 | $15.64 | $1.8M | 63,344 | Jan 20, 2026 |
| Jan 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -20,000 | - | - | 146,528 | Jan 20, 2026 |
| Jan 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -85,655 | - | - | 0 | Jan 20, 2026 |
| Jan 15, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -8,345 | - | - | 0 | Jan 20, 2026 |
Related signals
Other insiders at DYNAVAX TECHNOLOGIES CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 7Weak | DYNAVAX TECHNOLOGIES CORP | David F Novack President & COO | $465k 30,000 shares | -21% | |
| 24Weak | DVAXbuy DYNAVAX TECHNOLOGIES CORP | Scott Dunseth Myers director | $41k 3,800 shares | +12% | |
| 42Moderate | DVAXsell DYNAVAX TECHNOLOGIES CORP | Deep Track Biotechnology Master Fund, Ltd. owner | $22M 2,065,137 shares | -12% | |
| 16Weak | DYNAVAX TECHNOLOGIES CORP | David F Novack President & COO | $140k 10,000 shares | -55% | |
| 32Weak | DYNAVAX TECHNOLOGIES CORP | David F Novack President & COO | $190k 14,020 shares | -63% | |
| 37Weak | DYNAVAX TECHNOLOGIES CORP | David F Novack President & COO | $471k 32,764 shares | -60% | |
| 21Weak | DVAXsell DYNAVAX TECHNOLOGIES CORP | Francis Cano director | $43k 3,615 shares | -9% | |
| 33Weak | DVAXsell DYNAVAX TECHNOLOGIES CORP | Justin Burgess Chief Accounting Officer | $262k 20,526 shares | -100% | |
| 0Weak | DYNAVAX TECHNOLOGIES CORP | Robert Janssen SVP and CMO | $23k 1,500 shares | -3% | |
| 24Weak | DYNAVAX TECHNOLOGIES CORP | David F Novack President & COO | $130k 9,000 shares | -74% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.